Orbimed Advisors LLC Chinook Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $2.33 Million - $3.11 Million	133,000 Added 7.01%	2,029,300 $39.9 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $6.02 Million - $8.99 Million	478,000 Added 33.7%	1,896,300 $33.2 Million
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $24,982 - $39,331	-2,337 Reduced 0.16%	1,418,300 $23.1 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $998,614 - $1.29 Million	86,836 Added 6.51%	1,420,637 $18.1 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $1.14 Million - $1.59 Million	83,800 Added 6.7%	1,333,801 $18.8 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $14.9 Million - $26.1 Million	1,250,001 New	1,250,001 $19.8 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.